DigestRedComo funciona
Red
/
Empresas
Al
No verificado

Alzheon, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

13 Comunicados de prensa

Ver todos los comunicados de prensa
02/12/2025
Ciencia
Finanzas
Medicina - Varios
Asociaciones/Profesionales
Biotecnología
Sanidad
Farmacéutica
Salud
Industria
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
19/11/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
14/10/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
15/07/2025
Salud
Sanidad
Farmacéutica
Biotecnología
Web y redes sociales
Eventos
Industria
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
10/04/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
18/03/2025
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
25/02/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Eventos
Industria
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
07/01/2025
Mercado laboral
Eventos
Industria
Psiquiatría
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
18/09/2024
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
New Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0
23/07/2024
Psiquiatría
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Eventos
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference
Fuente
Alzheon, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0